6620.TWO Handa Pharmaceuticals Inc.

Healthcare Drug Manufacturers - Specialty & Generic Taiwan OTC Exchange
98.90 TWD
Close of Nov 5, 2026
62.75 155.00
Market cap
TWD 16.1B
P/E
35.8x
P/B
4.00x
ROE
4.3%
Dividend yield
1.47%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6620.TWO undervalued?

Graham number
Price98.90
Graham value39.20
Premium152.3%

6620.TWO trades 152.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Handa Pharmaceuticals Inc. fundamental analysis

No fundamental analysis for Handa Pharmaceuticals Inc. yet.

Handa Pharmaceuticals Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Handa Pharmaceuticals Inc.

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple scl…

Full company profile